Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Camrelizumab with HAIC and SBRT for HCC with Portal Vein Tumor Thrombus
ChiCTR2300078562Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoint: Progression-free survival (PFS). Planned start Dec 2023; status: not yet recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300078562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078562.